Soros Fund Management’s Crescent Biopharma CBIO Stock Holding History

Soros Fund Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-103	Closed	-$87K	–	295
2014 Q2	$87K	Buy	+103	New	+$103K	﹤0.01%	329

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

MSA

Mason Street Advisors Milwaukee, Wisconsin $1.11B AUM 12.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soros Fund Management's CBIO Position: Q3 2014 in Review

Soros Fund Management sold out of Crescent Biopharma (CBIO) in Q3 2014, closing a stake of 103 shares — an estimated $87K sold.

Soros Fund Management first reported a position in CBIO in Q2 2014 and held it in 1 quarter. The position peaked at $87K in Q2 2014. 27 funds tracked by Wall St. Rank hold CBIO as of Q3 2014.

Soros Fund Management reported no remaining Crescent Biopharma position as of Q3 2014 after selling out during the quarter.
Soros Fund Management sold 103 Crescent Biopharma shares in Q3 2014, an estimated $87K.
Soros Fund Management first reported a position in Crescent Biopharma in Q2 2014 and held it in 1 quarter.
Soros Fund Management's Crescent Biopharma position peaked at $87K in Q2 2014.
27 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2014.

Based on Soros Fund Management's 13F filing for Q3 2014, filed 14 Nov 2014.